“Our findings suggest that durvalumab did not improve outcomes compared with cetuximab in patients with HNSCC with contraindications to cisplatin,” the authors concluded. “These findings are ...

Durvalumab is recommended, within its marketing authorisation, as neoadjuvant treatment with platinum-based chemotherapy, then continued alone as adjuvant treatment, for treating non-small-cell lung ...

University of Sheffield experts said the drug durvalumab could reduce the recurrence of operable bladder cancer by a third Medical experts in Sheffield have hailed as a "game changer" trials of a ...

Durvalumab is an immunotherapy drug used for ... However, precise figures would require detailed pricing and duty structure analysis,” said Dr Mandeep Singh Malhotra, Director of Surgical ...

There is a commercial access agreement for durvalumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...